OM:CAMXPharmaceuticals
Camurus (OM:CAMX) Stock After FDA CRL For CAM2029 Assessing Whether Valuation Discount Still Holds
Camurus (OM:CAMX) is back in focus after the U.S. Food and Drug Administration issued a complete response letter for CAM2029, citing manufacturing issues at a third-party facility rather than concerns about the drug itself.
See our latest analysis for Camurus.
The CAM2029 complete response letter and Lilly collaboration sit against a mixed backdrop, with the stock’s latest share price at SEK539.0, a 30 day share price return of 5.79% and a three year total shareholder return of 95.72%. In...